Breast cancer is the most common cancer among women. To date, 22 common breast cancer susceptibility loci have been identified accounting for ~8% of the heritability of the disease. We attempted to replicate 72 promising associations from two independent genome-wide association studies (GWAS) in ~70,000 cases and ~68,000 controls from 41 case-control studies and 9 breast cancer GWAS. We identified three new breast cancer risk loci at 12p11 (rs10771399; P = 2.7 × 10 −35 ), 12q24 (rs1292011; P = 4.3 × 10 −19 ) and 21q21 (rs2823093; P = 1.1 × 10 −12 ). rs10771399 was associated with similar relative risks for both estrogen receptor (ER)-negative and ER-positive breast cancer, whereas the other two loci were associated only with ER-positive disease. Two of the loci lie in regions that contain strong plausible candidate genes: PTHLH (12p11) has a crucial role in mammary gland development and the establishment of bone metastasis in breast cancer, and NRIP1 (21q21) encodes an ER cofactor and has a role in the regulation of breast cancer cell growth.
Breast cancer is one of the most commonly occurring epithelial malignancies in women, with an estimated 1 million new cases and over 400,000 deaths annually worldwide 1 . Familial aggregation and twin studies have shown the substantial contribution of inherited susceptibility to breast cancer 2, 3 . Over the last 4 years, we and others have conducted several GWAS and reported breast cancer susceptibility variants at 21 loci [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , with an additional locus (CASP8) identified through a candidate gene approach 15 . These variants are associated with modest risks for the disease (per-allele odds ratios (ORs) of <1. 3) and explain ~8% of the excess familial risk of breast cancer, whereas other rarer high-and moderate-risk loci contribute less than 20%, suggesting that other loci remain to be identified 16 .
To identify additional breast cancer susceptibility loci, we selected 72 SNPs for analysis that were genotyped and found to be significantly associated with breast cancer at P < 0.0001 in either of two breast cancer GWAS in the UK (UK2 and British Breast Cancer Study (BBCS)) 17, 18 . We attempted to genotype these SNPs in up to 41 casecontrol studies through the Breast Cancer Association Consortium (BCAC). After quality control exclusions (see Online Methods), we analyzed data on 54,588 cases of invasive breast cancer, 2,401 cases of ductal carcinoma in situ (DCIS) and 58,098 controls. In addition, we used data from seven additional breast cancer GWAS from which summary results had been obtained on the basis of imputation to the HapMap 2 Utah residents of Northern and Western European ancestry (CEU) population. Results from the GWAS and BCAC replication were then combined to derive the overall evidence of association for each SNP based on 69,564 cases and 68,150 controls.
Three SNPs showed strong evidence for association in European women, consistent with the effect seen in the original GWAS ( Fig. 1 and Table 1 ). In each case, the genotype-specific ORs were consistent with an allele dosage (log-additive) model (Supplementary Table 1 ). The rs2823093 SNP showed some evidence of heterogeneity in the perallele ORs among studies in the replication stage (P = 0.002), with particularly marked associations in two studies (Hannover-Minsk Breast Cancer Study (HMBCS) and Rotterdam Breast Cancer Study (RBCS); Fig. 1 ). The association in the replication stage remained highly significant, however, even after exclusion of these two studies (P = 7.1 × 10 −7 ). The other two loci showed no evidence of heterogeneity among studies. Two additional SNPs at 17q21, rs2532348 and rs199523 (correlated at r 2 = 0.80 in the UK2 GWAS), gave more limited evidence of replication (P = 7.8 × 10 -5 and 0.0063, respectively) and reached P = 5.8 × 10 −7 and 2.6 × 10 −6 , respectively, when combined with the GWAS data (Supplementary Table 2 ). These SNPs were only genotyped in the UK2 GWAS. They could not be imputed using HapMap and were only successfully genotyped in 12 studies in the BCAC replication. Moreover, for rs2532348, there was evidence of heterogeneity among studies in the perallele ORs in BCAC (P = 0.001). Additional data will be required to determine whether this SNP is associated with breast cancer risk. Three other SNPs (rs10940235 at 5q11, rs4403040 at 4q21 and rs6027564 at 20q13) showed evidence of replication at P < 0.01, but none reached genomewide levels of statistical significance (Supplementary Table 2 ).
For women of Asian ancestry, rs10771399 (12p11) was also associated with breast cancer risk, with the estimated OR being similar to that in women of European ancestry (Supplementary Table 3 ). There was no significant evidence of association for either rs1292011 (12q24) or rs2823093 (21q21) in women of Asian ancestry. For rs2823093, the estimated OR was in the opposite direction from that in women of European ancestry, but the estimates did not differ significantly (Supplementary Table 3 ).
The rs10771399 SNP showed strong evidence of association with both ER-positive and ER-negative breast cancer, with the estimated per-allele ORs being similar (based on 24,775 ER-positive and 7,122 ER-negative cases; Supplementary Table 4a ). In contrast, for rs1292011 and rs2823093, the association was confined to ERpositive breast cancer, with no evidence of association for ER-negative disease (Supplementary Table 4a ). These latter results conform to the general pattern of a preponderance of common susceptibility loci for ER-positive disease identified through GWAS based on cases not selected for disease subtype 19, 20 . In terms of per-allele OR, rs10771399 had one of the strongest effects identified to date for ER-negative breast cancer (OR = 0.85, 95% confidence interval (CI) = 0.80-0.90). For all three SNPs, the per-allele ORs for DCIS was similar to those for invasive disease (based on up to 2,148 DCIS cases; Supplementary Table 4b ). For rs10771399, the estimated OR was higher for ten studies in which cases were selected for a positive family history and/or bilaterality, as would be expected under a polygenic model 21 (P = 0.027; Supplementary Table 5) ; however, exclusion of data from these studies made little difference to the estimated OR. There was no evidence for difference in the per-allele OR by age at diagnosis for any SNP (Supplementary Table 4c ).
The rs10771399 SNP lies in an ~300-kb linkage disequilibrium (LD) block at 12p11 that contains one known gene, PTHLH (encoding parathyroid hormone-like hormone isoform 1), also called PTHrP (parathyroid hormonerelated protein) (Fig. 2a) . PTHLH is expressed in a wide variety of tissues and in many malignancies, including 60% of breast tumors, and is required for normal mammary gland and bone development [22] [23] [24] [25] . During lactation, PTHrP is released by the mammary gland to regulate the transfer of calcium from the skeleton to the milk 26, 27 . Tumor-secreted PTHrP mimics the action of parathyroid hormone (PTH) by binding to its receptor PTH1R 28 , thereby promoting humoral hypercalcemia as well as metastasis of breast cancer cells to the bone 23, [29] [30] [31] . It has been suggested that PTHrP enhances tumorigenesis through its pro-proliferative and anti-apoptotic activities by promoting survival in cells subjected to apoptosis 32, 33 . However, conflicting data regarding the correlation of PTHLH expression levels and breast cancer survival have been reported 24, [34] [35] [36] . Moreover, a recent study found that loss of PTHrP accelerates tumor incidence in DCIS and is associated with monocyte infiltration 37 . l e t t e r s
The rs1292011 SNP at 12q24 lies in an ~100-kb LD block that contains no known genes (Fig. 2b) . SNPs in this region have been found to be associated with squamous esophageal carcinoma, renal cell carcinoma, liver adenoma, heart disease and type 1 diabetes as well as blood pressure and prostate-specific antigen (PSA) levels [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] . Two plausible cancer candidate genes, MAPKAPK5 (encoding mitogenactivated protein kinase-activated protein kinase 5; also called MK5 or PRAK) and TBX3 (encoding T-box 3), lie within 2 Mb of rs1292011. The MAPKAPK5 protein is a member of the serine/threonine kinase family, and MAPKAPK5 is directly activated by Myc 48 . TBX3 has a role in mammary gland development 49 , and haploinsufficiency for TBX3 is associated with ulnar-mammary disorder 50 . TBX3 was found to be amplified and overexpressed in several cancers, including breast cancer [51] [52] [53] [54] , and TBX3 was at high levels in plasma from individuals with breast and ovarian cancer 52 . Recently, it has been shown that estrogen regulates the expansion of breast cancer stem cells through the fibroblast growth factor (FGF)-FGF receptor (FGFR)-TBX3 pathway 52, 55 and that TBX3 is a direct downstream target of the Wnt-β-catenin pathway 56 . The expression of TBX3 was found to be significantly higher (P < 0.0001) in ER-positive breast cancer tumors than in ER-negative tumors in two independent data sets containing 781 tumors (using expression data from the Human Genome HG 133A Affymetrix array) 57 and 244 tumors (using expression data from the Human Agilent 44k microarray) 58 . These data suggest that the association of rs1292011 with ER-positive breast cancer could be mediated through its effect on TBX3.
The rs2823093 SNP lies in an ~130-kb LD block containing no known genes. The nearest gene, ~900 kb downstream, is NRIP1 (encoding nuclear receptor-interacting protein 1) (Fig. 2c) , also called RIP140 (receptor-interacting protein 140). RIP140 acts as a strong transcriptional repressor for nuclear receptors 59, 60 . It interacts with estrogen receptor α (ERα), represses ER signaling and inhibits its mitogenic effects 61 . This repression is mediated through interaction with FHL1, a protein involved in suppressing cancer cell growth and migration 62 . Several lines of evidence suggest that RIP140 has an important role in the regulation of breast cancer cell growth. Knockdown of RIP140 was found to induce growth promotion in an ER-positive breast cancer cell line 61 . The RIP140 protein was also highly induced following the treatment of human breast cancer cells with retinoids, known for their breast cancer growth suppression and anti-estrogenic effects [63] [64] [65] [66] . A Spanish case-control study, which genotyped SNPs in 91 breast cancer candidate genes in ~700 cases and ~700 controls, identified a relatively rare SNP at this locus (rs926184; minor allele frequency (MAF) of ~2%) located 175 kb upstream of rs2823093, which showed a modest association with breast cancer 67 . These two SNPs, however, are not correlated (r 2 = 0 in the HapMap CEU population). The expression of NRIP1 has been shown to be significantly higher in ER-positive tumors relative to ER-negative ones (P < 0.0001) 57, 58 , suggesting that the association of rs28323093 with ER-positive breast cancer could be mediated through its effect on NRIP1 expression 57, 58 .
The three susceptibility variants newly identified in this study are relatively common (MAFs of 0.11-0.41) and together explain ~0.7% of the familial risk of breast cancer and bring the total contribution of common low-penetrance breast cancer susceptibility loci to ~9%. The relative risks associated with these variants are modest, with the per-allele ORs for the risk alleles ranging from 1.07-to 1.22-fold, but the causal variants underlying some of these loci might confer more substantial risks. The present work highlights the importance of combining GWAS and large-scale replication studies with tumor subtyping in the identification and characterization of breast cancer susceptibility loci. 
l e t t e r s
The genes in these regions (if proven to be the causal genes) underscore that diverse mechanisms are likely to be relevant to breast cancer pathogenesis. Re-sequencing of these loci, combined with fine-scale mapping and functional analyses, will provide greater insights into the genetic architecture of breast cancer and the pathogenesis of the disease.
URLs. HapMap, http://hapmap.ncbi.nlm.nih.gov/.
METhodS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website. FBCS organized patient recruitment and data and sample collection for the UK2 GWAS. The GENICA Network organized patient recruitment and data and sample collection for the GENICA study. kConFab investigators and the Australian Ovarian Cancer Study organized recruitment and data and sample collection for kConFab and AOCS, respectively.
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